JP2008255043A - Skincare preparation for external use - Google Patents
Skincare preparation for external use Download PDFInfo
- Publication number
- JP2008255043A JP2008255043A JP2007098043A JP2007098043A JP2008255043A JP 2008255043 A JP2008255043 A JP 2008255043A JP 2007098043 A JP2007098043 A JP 2007098043A JP 2007098043 A JP2007098043 A JP 2007098043A JP 2008255043 A JP2008255043 A JP 2008255043A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- formulation
- effect
- cyclocarya paliurus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 37
- 241000124033 Salix Species 0.000 claims description 13
- 230000000694 effects Effects 0.000 abstract description 24
- 102000029816 Collagenase Human genes 0.000 abstract description 12
- 108060005980 Collagenase Proteins 0.000 abstract description 12
- 229960002424 collagenase Drugs 0.000 abstract description 12
- 230000002292 Radical scavenging effect Effects 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 241000233779 Cyclocarya paliurus Species 0.000 abstract 4
- 241000758791 Juglandaceae Species 0.000 abstract 1
- 206010040829 Skin discolouration Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 32
- 238000009472 formulation Methods 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 23
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000008213 purified water Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229940058015 1,3-butylene glycol Drugs 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 235000019437 butane-1,3-diol Nutrition 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- -1 lipid peroxides Chemical class 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003788 bath preparation Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000233778 Cyclocarya Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、青銭柳の抽出物を含有することにより、老化防止と美白作用に優れた皮膚外用剤に関する。 The present invention relates to a skin external preparation excellent in anti-aging and whitening action by containing an extract of green willow.
近年、生体成分を酸化させる要因として、フリーラジカルや活性酸素がとりあげられ、その悪影響が問題となっている。フリーラジカルや活性酸素は、生体内で生じ、コラーゲン等の生体組織を分解あるいは架橋し、また、脂質を酸化して、細胞に障害を与える過酸化脂質をつくると言われている。この様な障害は、肌のシワやハリが低下する等の老化の原因になると考えられており、老化を防ぐ方法の一つにフリーラジカルや活性酸素を除去する抗酸化剤を配合する方法が知られている。従来、老化防止を目的として用いられるフリーラジカル消去剤にはアスコルビン酸、トコフェロール、3,5−tert−ブチル−4−ヒドロキシトルエン(BHT)、スーパーオキシドジスムターゼ(SOD)等が用いられてきた。 In recent years, free radicals and active oxygen have been taken up as factors that oxidize biological components, and their adverse effects have become a problem. It is said that free radicals and active oxygen are generated in the living body, decompose or cross-link biological tissues such as collagen, and oxidize lipids to form lipid peroxides that damage cells. Such disorders are thought to cause aging such as wrinkles and firmness of the skin, and one method of preventing aging is to incorporate an antioxidant that removes free radicals and active oxygen. Are known. Conventionally, ascorbic acid, tocopherol, 3,5-tert-butyl-4-hydroxytoluene (BHT), superoxide dismutase (SOD) and the like have been used as free radical scavengers used for the purpose of preventing aging.
皮膚は、表皮、真皮、皮下組織からなるが、中でも真皮は皮膚の構造維持に極めて重要であり、ヒアルロン酸、コラーゲン等から形成される真皮結合組織によって皮膚のハリが保たれている。この結合組織が収縮力を失い、さらに弾力を失う結果として皮膚のシワやタルミが発生すると考えられている。 The skin is composed of epidermis, dermis, and subcutaneous tissue. Among them, the dermis is extremely important for maintaining the structure of the skin, and the elasticity of the skin is maintained by the dermal connective tissue formed from hyaluronic acid, collagen, and the like. It is believed that this connective tissue loses its contractile force and loses its elasticity, resulting in skin wrinkles and sagging.
また、皮膚が紫外線を浴びるとコラゲナーゼ等のマトリックスメタロプロテアーゼが活性化されることが知られている。これらの酵素は、真皮の主要成分であるコラーゲンを減少させることによりシワやタルミを促進すると言われている。 It is also known that matrix metalloproteases such as collagenase are activated when the skin is exposed to ultraviolet rays. These enzymes are said to promote wrinkles and tarmi by reducing collagen, which is a major component of the dermis.
近年、この皮膚のシワやタルミ等を防止する多くの化粧料が知られ、その有効成分としてレチノイン酸、α−ヒドロキシ酸、レチノール等が報告されている。しかしながら、これらの有効成分は皮膚刺激性や安定性に問題がある。また、シワやタルミを防ぐ方法の一つに、コラゲナーゼ活性阻害剤を配合することが知られている。 In recent years, many cosmetics for preventing wrinkles, tarmi and the like of this skin are known, and retinoic acid, α-hydroxy acid, retinol and the like have been reported as active ingredients. However, these active ingredients have problems with skin irritation and stability. In addition, it is known to add a collagenase activity inhibitor as one of the methods for preventing wrinkles and tarmi.
一般にシミ、ソバカス、日焼け等に見られる皮膚の色素沈着は、ホルモンの異常や紫外線の刺激により、皮膚内に存在するメラニン色素生成細胞がメラニン色素を過剰に生成し、これが皮膚内に沈着することが原因と考えられている。このような色素沈着を防ぐ方法の一つに、メラニンの過剰な生成を抑制する方法が知られている。従来、色素沈着の治療にはハイドロキノンやアスコルビン酸等を外用する処置が行われてきた。
しかし、以上に述べた老化防止及び美白作用の指標であるラジカル消去作用、コラゲナーゼ活性阻害作用、メラニン生成抑制作用について、植物原料の青銭柳は検討されていなかった。
In general, pigmentation of the skin seen in spots, buckwheat, sunburn, etc. is caused by excessive melanin pigment formation by melanin-producing cells present in the skin due to hormonal abnormalities or stimulation of ultraviolet rays, which deposits in the skin. Is considered to be the cause. As one method for preventing such pigmentation, a method for suppressing excessive production of melanin is known. Conventionally, treatments for external application of hydroquinone, ascorbic acid or the like have been performed for the treatment of pigmentation.
However, the plant raw material Seiyanagi has not been studied for the radical scavenging action, collagenase activity inhibitory action, and melanin production inhibitory action, which are the indicators of anti-aging and whitening actions described above.
皮膚の老化防止又は抗酸化を目的として用いられるSODは不安定であり、製剤化が難しく、トコフェロールも効果が充分であるとは言えない。また、合成化合物であるBHT等は安全性に問題があり、配合量に制限があることから、化学合成品ではなく、安定でかつ副作用の少ない天然原料が望まれている。同様に、安全で安定なコラゲナーゼ活性阻害作用を有することが老化防止に好ましい。また、美白剤して用いられるアスコルビン酸は経時的に分解しやすい等の欠点があるため、同様に安定性が高く、効果の優れた天然物由来の皮膚外用剤が望まれている。
以上のことから、安全で安定性に優れ、老化防止及び美白作用に優れた皮膚外用剤が望まれている。
SOD used for the purpose of preventing skin aging or anti-oxidation is unstable, difficult to formulate, and tocopherol is not effective enough. Moreover, since BHT etc. which are synthetic compounds have a problem in safety | security and there exists a restriction | limiting in compounding quantity, it is not a chemical synthetic product but the natural raw material which is stable and has few side effects is desired. Similarly, it is preferable for preventing aging that it has a safe and stable collagenase activity inhibitory action. In addition, since ascorbic acid used as a whitening agent has drawbacks such as being easily decomposed over time, a skin external preparation derived from natural products having high stability and excellent effect is also desired.
From the above, a skin external preparation that is safe and excellent in stability, excellent in anti-aging and whitening action is desired.
このような事情により、本発明者らは鋭意検討した結果、青銭柳の抽出物が優れたDPPHラジカル消去作用、コラゲナーゼ活性阻害作用及びメラニン生成抑制作用をもち、安定性においても優れていることを見出した。さらに、その抽出物を含有する皮膚外用剤が、安全で安定であり、老化防止及び美白作用に優れていることを見出し、本発明を完成するに至った。 Under these circumstances, as a result of intensive studies, the present inventors have found that the extract of Seijyanagi has excellent DPPH radical scavenging action, collagenase activity inhibitory action and melanin production inhibitory action, and is also excellent in stability. I found. Furthermore, it discovered that the skin external preparation containing the extract was safe and stable, and was excellent in anti-aging and whitening effect, and came to complete this invention.
本発明に用いる青銭柳(クルミ科、別名;ゼニガタ、キクロカーヤ)は、学名がCyclocarya paliurus(シクロカリヤ パリウラス)で中国が原産である。砂糖の200倍の甘さを示すシクロカリオシドが含まれ、甘味のあるお茶として飲用され、糖尿病や高血圧によいとされている。なお、本植物は、化粧料としての利用は報告されていない。 Seianyanagi used in the present invention (Walmiaceae, also known as Zenigata, Kikurokaya) is scientifically named Cyclocarya pariurus and is native to China. It contains cyclocaryoside, which is 200 times sweeter than sugar, and is drunk as a sweet tea. It is said to be good for diabetes and high blood pressure. The plant has not been reported for use as a cosmetic.
本発明に用いる青銭柳の抽出物とは、植物体の葉、茎、樹皮、花、実、根等の植物体の一部又は全草から抽出したものである。好ましくは、植物体の葉から抽出して得られるものが良い。その抽出方法は特に限定されず、例えば、加熱抽出したものであっても良いし、常温抽出したものであっても良い。 The extract of the green willow used in the present invention is extracted from a part of the plant body such as leaves, stems, bark, flowers, fruits and roots of the plant body or the whole plant. Preferably, those obtained by extraction from the leaves of the plant body are good. The extraction method is not particularly limited, and for example, it may be a heat extraction or a room temperature extraction.
抽出する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、1,3−ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は一種でも二種以上を混合して用いても良い。 Examples of the solvent to be extracted include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol). , Glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether) Etc.). Preferred are polar solvents such as water, lower alcohols and liquid polyhydric alcohols, and particularly preferred are water, ethanol, 1,3-butylene glycol and propylene glycol. These solvents may be used alone or in combination of two or more.
上記抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、希釈及び濾過処理、活性炭等による脱色、脱臭処理等をして用いても良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良い。 The extract may be used as it is, or may be used after concentration, dilution and filtration treatment, decolorization with activated carbon, deodorization treatment, or the like, if necessary. Further, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.
本発明の皮膚外用剤には、上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤等の成分を配合することができる。 In the external preparation for skin of the present invention, the above extract may be used as it is, and within the range not impairing the effect of the extract, oils and fats, waxes, hydrocarbons, fatty acids which are components used in the external preparation , Alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, fragrances, moisturizers, powders, UV absorbers, thickeners, pigments, antioxidants, whitening agents, chelating agents, etc. These components can be blended.
本発明の皮膚外用剤は、化粧品、医薬部外品、医薬品のいずれにも用いることができ、その剤形としては、例えば、化粧水、クリ−ム、乳液、ゲル剤、エアゾール剤、エッセンス、パック、洗浄剤、浴用剤、ファンデ−ション、打粉、口紅、軟膏、パップ剤等の皮膚に適用されるものが挙げられる。 The external preparation for skin of the present invention can be used for any of cosmetics, quasi drugs, and pharmaceuticals. Examples of the dosage form include skin lotions, creams, emulsions, gels, aerosols, essences, Examples include packs, cleaning agents, bath preparations, foundations, dusting powders, lipsticks, ointments, and poultices applied to the skin.
本発明に用いる上記抽出物の配合量は、本発明の皮膚外用剤全量に対し、固形物に換算して0.0001重量%以上、好ましくは0.001〜10重量%の配合が良い。0.0001重量%未満では十分な効果は望みにくい。10重量%を越えて配合した場合、効果の増強は認められにくく不経済である。また、添加の方法については、予め加えておいても、製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。 The amount of the extract used in the present invention is 0.0001% by weight or more, preferably 0.001 to 10% by weight in terms of solid matter, based on the total amount of the external preparation for skin of the present invention. If it is less than 0.0001% by weight, a sufficient effect is hardly expected. When the blending amount exceeds 10% by weight, the effect is hardly recognized and it is uneconomical. In addition, the addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.
本発明の青銭柳の抽出物は、優れたDPPHラジカル消去作用、コラゲナーゼ活性阻害及びメラニン生成抑制作用を有し、安定性にも優れていた。さらに、これらの抽出物を含有する皮膚外用剤は、安全で優れた老化防止及び美白作用を示した。 The Seiyanagi extract of the present invention had excellent DPPH radical scavenging action, collagenase activity inhibition and melanin production inhibition action, and was also excellent in stability. Furthermore, the external preparation for skin containing these extracts showed safe and excellent anti-aging and whitening action.
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、本発明の処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す配合量の部とは重量部を、%とは重量%を示す。 Next, in order to describe the present invention in detail, examples of producing the extract used in the present invention, formulation examples and experimental examples of the present invention will be given as examples, but the present invention is not limited thereto. In the examples, the part of the amount is part by weight, and% is% by weight.
製造例1 青銭柳の熱水抽出物
青銭柳の葉の乾燥物30gに精製水900mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して青銭柳の熱水抽出物を3.3g得た。
Manufacture example 1 Hot water extract of green sen willow 900 mL of purified water is added to 30 g of dried sen willow leaves, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate is concentrated and lyophilized. 3.3 g of hot water extract of green senyanagi was obtained.
製造例2 青銭柳のエタノール抽出物
青銭柳の葉の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、青銭柳のエタノール抽出物を9.5g得た。
Manufacture example 2 Ethnic extract of green willow leaves 1 g of ethanol is added to 100 g of dried leaves of green willow leaves, extracted at room temperature for 7 days, filtered, and the filtrate is concentrated to dryness. 9.5 g of extract was obtained.
製造例3 青銭柳の50%1,3−ブチレングリコール抽出物
青銭柳の葉及び樹皮の乾燥物20gに精製水200g及び1,3−ブチレングリコール200gを加え、常温で7日間抽出した後、濾過し、青銭柳の50%1,3−ブチレングリコール抽出物を360g得た。
Manufacture example 3 50% 1,3-butylene glycol extract of green sen willow After adding 200 g of purified water and 200 g of 1,3-butylene glycol to 20 g of dry leaves of green sen willow and bark, and extracting at room temperature for 7 days And filtered to obtain 360 g of 50% 1,3-butylene glycol extract of Seishenyanagi.
処方例1 化粧水
処方 配合量
1.青銭柳の熱水抽出物(製造例1) 0.1部
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1〜6及び11と、成分7〜10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Formulation Example 1 Lotion Formulation Amount Seianyanagi hot water extract (Production Example 1) 0.1 part 2.1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5. Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Perfume
11. [Manufacturing method] Components 1 to 6 and 11 and components 7 to 10 are uniformly dissolved in purified water, and both are mixed and filtered to obtain a product.
比較例1 従来の化粧水
処方例1において、青銭柳の熱水抽出物を精製水に置き換えたものを従来の化粧水とした。
Comparative Example 1 Conventional Lotion A conventional lotion was obtained by replacing the hot water extract of Seijyanagi with purified water in Formulation Example 1.
処方例2 クリーム
処方 配合量
1.青銭柳のエタノール抽出物(製造例2) 0.05部
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.パラオキシ安息香酸メチル 0.2
12.パラオキシ安息香酸エチル 0.05
13.1,3−ブチレングリコール 8.5
14.精製水にて全量を100とする
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
Formulation Example 2 Cream Formulation Amount Seienyanagi ethanol extract (Production Example 2) 0.05 part Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5. Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12 Ethyl paraoxybenzoate 0.05
13.1,3-Butylene glycol 8.5
14 [Manufacturing method] Components 2 to 9 are heated and dissolved and mixed with purified water to a total amount of 100, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11 to 14 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
比較例2 従来のクリーム
処方例2において、青銭柳のエタノール抽出物を精製水に置き換えたものを従来のクリームとした。
Comparative Example 2 Conventional Cream In Formulation Example 2, a product obtained by substituting the ethanol extract of Seishiyanagi with purified water was used as a conventional cream.
処方例3 乳液
処方 配合量
1.青銭柳の熱水抽出物(製造例1) 0.001部
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート
(20E.O.) 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水にて全量を100とする
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分1及び10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
Formulation Example 3 Emulsion Formulation Formulation 1. 1. Hot spring extract of blue sen willow (Production Example 1) 0.001 part Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5. Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. Make the total volume 100 with purified water
[Manufacturing method] Components 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 9 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
処方例4 ゲル剤
処方 配合量
1.青銭柳の50%1,3−ブチレングリコール抽出物
(製造例3) 1.0部
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5.香料 適量
6.1,3−ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水にて全量を100とする
[製造方法]成分2〜5と、成分1及び6〜11をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation Example 4 Gel formulation Formulation amount 1. 1. 50 parts 1,3-butylene glycol extract of Seishiyanagi (Production Example 3) 1.0 part Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
5. Perfume
6.1,3-Butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. [Production method] Ingredients 2 to 5 and ingredients 1 and 6 to 11 are uniformly dissolved in purified water, and the two are mixed to obtain a product.
処方例5 パック
処方 配合量
1.青銭柳の熱水抽出物(製造例1) 0.1部
2.青銭柳のエタノール抽出物(製造例2) 0.1
3.ポリビニルアルコール 12.0
4.エタノール 5.0
5.1,3−ブチレングリコール 8.0
6.パラオキシ安息香酸メチル 0.2
7.ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
8.クエン酸 0.1
9.クエン酸ナトリウム 0.3
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1〜11を均一に溶解し製品とする。
Formulation Example 5 Pack Formulation Formulation 1. 1. Hot water extract of blue sen willow (Production Example 1) 0.1 part Seianyanagi ethanol extract (Production Example 2) 0.1
3. Polyvinyl alcohol 12.0
4). Ethanol 5.0
5.1,3-Butylene glycol 8.0
6). Methyl paraoxybenzoate 0.2
7). Polyoxyethylene hydrogenated castor oil (20 EO) 0.5
8). Citric acid 0.1
9. Sodium citrate 0.3
10. Perfume proper amount11. [Production Method] Components 1 to 11 are uniformly dissolved in purified water to make a total amount of 100 to obtain a product.
処方例6 ファンデーション
処方 配合量
1.青銭柳のエタノール抽出物(製造例2) 1.0部
2.ステアリン酸 2.4
3.ポリオキシエチレンソルビタンモノステアレート
(20E.O.) 1.0
4.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5.セタノール 1.0
6.液状ラノリン 2.0
7.流動パラフィン 3.0
8.ミリスチン酸イソプロピル 6.5
9.カルボキシメチルセルロースナトリウム 0.1
10.ベントナイト 0.5
11.プロピレングリコール 4.0
12.トリエタノールアミン 1.1
13.パラオキシ安息香酸メチル 0.2
14.二酸化チタン 8.0
15.タルク 4.0
16.ベンガラ 1.0
17.黄酸化鉄 2.0
18.香料 適量
19.精製水にて全量を100とする
[製造方法]成分2〜8を加熱溶解し、80℃に保ち油相とする。成分19に成分9をよく膨潤させ、続いて、成分1及び10〜13を加えて均一に混合する。これに粉砕機で粉砕混合した成分14〜17を加え、ホモミキサーで撹拌し75℃に保ち水相とする。この水相に油相をかき混ぜながら加え、冷却し、45℃で成分18を加え、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 6 Foundation Formulation Amount Ao-shiyanagi ethanol extract (Production Example 2) 1.0 part Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20EO) 1.0
4). Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Cetanol 1.0
6). Liquid lanolin 2.0
7). Liquid paraffin 3.0
8). Isopropyl myristate 6.5
9. Sodium carboxymethylcellulose 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12 Triethanolamine 1.1
13. Methyl paraoxybenzoate 0.2
14 Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Perfume proper amount19. [Manufacturing method] Components 2 to 8 are heated and dissolved in purified water to a total amount of 100, and kept at 80 ° C to obtain an oil phase. Swell component 9 well in component 19, then add components 1 and 10-13 and mix uniformly. To this, components 14 to 17 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The oil phase is added to this aqueous phase with stirring, cooled, component 18 is added at 45 ° C., and cooled to 30 ° C. with stirring to give a product.
実施例7 浴用剤
処方 配合量
1.青銭柳の熱水抽出物(製造例1) 5.0部
2.炭酸水素ナトリウム 50.0
3.黄色202号(1) 適量
4.香料 適量
5.硫酸ナトリウムにて全量を100とする
[製造方法]成分1〜5を均一に混合し製品とする。
Example 7 Bath preparation formulation 1. Hot water extract of blue sen willow (Production Example 1) 5.0 parts Sodium bicarbonate 50.0
3. Yellow No. 202 (1) Appropriate amount 4. Perfume appropriate amount 5. [Manufacturing method] Ingredients 1 to 5 are mixed uniformly with sodium sulfate to make a product.
処方例8 軟膏
処方 配合量
1.青銭柳の熱水抽出物(製造例1) 0.01部
2.青銭柳の50%1,3−ブチレングリコール抽出物
(製造例3) 0.5
3.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
4.モノステアリン酸グリセリン 10.0
5.流動パラフィン 5.0
6.セタノール 6.0
7.パラオキシ安息香酸メチル 0.1
8.プロピレングリコール 10.0
9.精製水にて全量を100とする
[製造方法]成分3〜6を加熱溶解して混合し、70℃に保ち油相とする。成分1、2及び7〜9を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
次に、本発明の効果を詳細に説明するため、実験例を挙げる。
Formulation Example 8 Ointment Formulation Formulation 1. Hot water extract of blue sen willow (Production Example 1) 0.01 part2. 50% 1,3-butylene glycol extract of blue senyanagi (Production Example 3) 0.5
3. Polyoxyethylene cetyl ether (30E.O.) 2.0
4). Glycerol monostearate 10.0
5. Liquid paraffin 5.0
6). Cetanol 6.0
7). Methyl paraoxybenzoate 0.1
8). Propylene glycol 10.0
9. [Production Method] Components 3 to 6 are heated and dissolved and mixed with purified water to a total amount of 100, and kept at 70 ° C. to obtain an oil phase. Ingredients 1, 2, and 7-9 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.
Next, experimental examples will be given to explain the effects of the present invention in detail.
実験例1 DPPHラジカル消去作用
製造例1、2を試料として用い、フリーラジカルの一種であるDPPHラジカルの消去作用を測定した。陽性対照として、アスコルビン酸を用いた。また、試料の安定性を確認するために、試料を40℃で2週間保存して同様に測定を行った。
Experimental Example 1 DPPH Radical Scavenging Action Using Production Examples 1 and 2 as samples, the scavenging action of DPPH radical, a kind of free radical, was measured. Ascorbic acid was used as a positive control. In addition, in order to confirm the stability of the sample, the sample was stored at 40 ° C. for 2 weeks and measured in the same manner.
各濃度の試料水溶液0.3mLに0.1mLの酢酸緩衝液(pH5.5)と0.4mLのエタノールと0.2mLの0.5mMのDPPH(diphenylpycrylhydrazyl)エタノール溶液を加え、37℃で30分間反応させた後、波長517nmにおける吸光度を測定した。各試料の消去率は、次の式で算出した。
消去率(%)=(1−試料吸光度/ブランク吸光度)×100
これらの試験結果を表1に示した。アスコルビン酸は40℃で2週間の保存により、DPPHラジカル消去作用が大きく減少したが、青銭柳の抽出物は消去作用に変化はなかった。以上のことから、青銭柳の抽出物は、安定で優れたDPPHラジカル消去作用を示した。
To 0.3 mL of the sample aqueous solution of each concentration, add 0.1 mL of acetate buffer (pH 5.5), 0.4 mL of ethanol, and 0.2 mL of 0.5 mM DPPH (diphenylcyclic hydrazyl) ethanol solution at 37 ° C. for 30 minutes. After the reaction, the absorbance at a wavelength of 517 nm was measured. The erasure rate of each sample was calculated by the following formula.
Erase rate (%) = (1-sample absorbance / blank absorbance) × 100
The test results are shown in Table 1. Ascorbic acid significantly reduced the DPPH radical scavenging action after storage at 40 ° C. for 2 weeks, but the extract of Seijyanagi did not change the scavenging action. From the above, the extract of Seijyanagi showed a stable and excellent DPPH radical scavenging action.
実験例2 コラゲナーゼ活性阻害作用
製造例1、2を試料として用い、コラゲナーゼ活性阻害作用を測定した。マイクロプレートを用いて、試料液50μLに酵素液として0.1mg/mLのコラゲナーゼ Type IV(シグマ製)水溶液を50μL加えた。基質溶液として0.39mg/mLのPz−ペプタイド(Pz−Pro−Leu−Gly−Pro−D−Arg−OH、シグマ製)・20mM塩化カルシウム入りトリス塩酸緩衝液(pH7.1)を加えて混合し、37℃、30分反応させた後、1mLの25mMクエン酸を加えて反応を停止させた。5mLの酢酸エチルを加えて抽出して、酢酸エチル層を320nmの吸光度を測定した。また、各試料の阻害作用は、次の式から求められる阻害率で算出した。なお、対照には試料の代わりに精製水を用い、ブランクとしてコラゲナーゼの代わりに20mM塩化カルシウム入りトリス塩酸緩衝液(pH7.1)を用いた。
阻害率(%)=〔1−(C−D)/(A−B)〕×100
A:対照の320nmにおける吸光度(O.D.320)
B:対照ブランクのO.D.320
C:試料のO.D.320
D:試料ブランクのO.D.320
Experimental Example 2 Collagenase activity inhibitory action Using Production Examples 1 and 2 as samples, the collagenase activity inhibitory action was measured. Using a microplate, 50 μL of 0.1 mg / mL collagenase Type IV (Sigma) aqueous solution was added as an enzyme solution to 50 μL of the sample solution. Add and mix 0.39 mg / mL Pz-peptide (Pz-Pro-Leu-Gly-Pro-D-Arg-OH, Sigma) / 20 mM calcium chloride-containing Tris-HCl buffer (pH 7.1) as a substrate solution. Then, after reacting at 37 ° C. for 30 minutes, 1 mL of 25 mM citric acid was added to stop the reaction. Extraction was performed by adding 5 mL of ethyl acetate, and the absorbance of the ethyl acetate layer was measured at 320 nm. Moreover, the inhibitory action of each sample was calculated by the inhibition rate calculated | required from the following formula. For the control, purified water was used instead of the sample, and 20 mM calcium chloride-containing Tris-HCl buffer (pH 7.1) was used instead of collagenase as a blank.
Inhibition rate (%) = [1- (C−D) / (A−B)] × 100
A: Absorbance at 320 nm of control (OD 320)
B: O. D. 320
C: Sample O.D. D. 320
D: Sample blank O.D. D. 320
これらの実験結果を表2に示した。その結果、青銭柳の抽出物は優れたコラゲナーゼ活性阻害作用を示した。
The results of these experiments are shown in Table 2. As a result, Seiyanagi extract showed an excellent collagenase activity inhibitory action.
実験例3 B16マウスメラノーマを用いたメラニン生成抑制試験
製造例1、2を試料として用い、メラニン生成抑制作用を測定した。
Experimental Example 3 Melanin Production Inhibition Test Using B16 Mouse Melanoma Using Production Examples 1 and 2 as samples, the melanin production inhibitory action was measured.
マウスメラノーマ由来細胞株であるB16細胞を6cmディッシュに3×104個播種し、10%FBSを含むMEM with NEAAにて5%CO2、37℃条件下で5日間培養した。その時、それぞれの試料は、最終濃度を調整して添加した。次に、細胞をPBS(−)にて2回洗浄した後、PBS(−)1mLを加え、ラバーポリスマンにて集めた。遠心操作をして得られたペレットにPBS(−)0.5mLを加え、超音波破砕操作をしてペレットを溶解させた。タンパク定量はLowry法{Lowry,O.H.et al.,J.Biol.Chem.,193,265−275(1951)}により測定した。また、1mgタンパクあたりのメラニン量を測定する場合、タンパク定量用に取った残りの細胞破砕溶液に4N水酸化ナトリウム0.5mLを加え、60℃で2時間反応させた後O.D.475を測定し、検量線からメラニン定量を行った。データは1mgタンパクあたりのメラニン量を算出し、試料未添加のメラニン生成量をコントロールとし、コントロールに対する試料添加時のメラニン生成抑制量の値をメラニン抑制率とした。 B16 cells, a mouse melanoma-derived cell line, were seeded at 3 × 10 4 cells in a 6 cm dish, and cultured for 5 days in MEM with NEAA containing 10% FBS under 5% CO 2 and 37 ° C. conditions. At that time, each sample was added after adjusting the final concentration. Next, after the cells were washed twice with PBS (−), 1 mL of PBS (−) was added and collected with a rubber policeman. PBS (-) 0.5mL was added to the pellet obtained by centrifugation, and the pellet was dissolved by ultrasonic crushing operation. Protein quantification was performed using the Lowry method {Lowry, O. H. et al. , J .; Biol. Chem. , 193, 265-275 (1951)}. When measuring the amount of melanin per mg protein, 0.5 mL of 4N sodium hydroxide was added to the remaining cell disruption solution taken for protein quantification and reacted at 60 ° C. for 2 hours. D. 475 was measured, and melanin was determined from the calibration curve. The data was calculated as the amount of melanin per mg protein, the amount of melanin not added to the sample was taken as a control, and the value of the amount of melanin inhibition when the sample was added relative to the control was taken as the melanin inhibition rate.
これらの実験結果を表3に示した。青銭柳の抽出物は、低濃度において優れたメラニン生成抑制作用を示した。 The results of these experiments are shown in Table 3. Seiyanagi extract showed an excellent inhibitory effect on melanin production at low concentrations.
実験例4 使用試験1
処方例1の化粧水、処方例2のクリーム、比較例1の従来の化粧水及び比較例2の従来のクリームを用いて、女性20人(21〜46才)を対象に1ヶ月間の使用試験を行った。使用後、肌のシワ、タルミの改善効果をアンケートにより判定した。
Experimental example 4 Use test 1
One month use for 20 women (21 to 46 years old) using the lotion of Formulation Example 1, the cream of Formulation Example 2, the conventional lotion of Comparative Example 1 and the conventional cream of Comparative Example 2. A test was conducted. After use, the effect of improving skin wrinkles and tarmi was determined by a questionnaire.
これらの試験結果を表4に示した。青銭柳の抽出物を含有する皮膚外用剤は優れたシワ、タルミの改善作用を示した。なお、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。また、処方成分の劣化についても問題なかった。 The test results are shown in Table 4. The topical skin preparation containing the extract of blue senyanagi showed excellent wrinkle and tarmi improving effects. During the test period, there was no skin problem and there was no problem with safety. There was also no problem with the deterioration of the prescription ingredients.
実験例5 使用試験2
処方例1の化粧水、処方例2のクリーム、比較例1の従来の化粧水及び比較例2の従来のクリームを用いて、シミ、ソバカスに悩む女性20人(21〜46才)を対象に1ヶ月間の使用試験を行った。使用後、シミ、ソバカスの改善効果をアンケートにより判定した。
Experiment 5 Use test 2
Using the lotion of Formulation Example 1, the cream of Formulation Example 2, the conventional lotion of Comparative Example 1 and the conventional cream of Comparative Example 2, targeting 20 women (21 to 46 years old) who suffer from spots and freckles A one month use test was conducted. After use, the effect of improving spots and freckles was judged by a questionnaire.
これらの試験結果を表5に示した。青銭柳の抽出物を含有する皮膚外用剤は、優れたシミ、ソバカスの改善作用を示した。なお、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。また、処方成分の劣化についても問題なかった。 The test results are shown in Table 5. The topical skin preparation containing the extract of blue sen willows showed an excellent effect of improving spots and freckles. During the test period, there was no skin problem and there was no problem with safety. There was also no problem with the deterioration of the prescription ingredients.
実施例3〜8についても同様に使用試験を行ったところ、優れたシワ、タルミ、シミ、ソバカス等の改善作用を示した。
When the usage test was similarly conducted on Examples 3 to 8, excellent wrinkle, tarmi, stain, buckwheat and other improving effects were shown.
Claims (2)
The skin external preparation according to claim 1, wherein the content of the extract using the leaves of green sen willow is 0.001 to 10%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007098043A JP5138262B2 (en) | 2007-04-04 | 2007-04-04 | Topical skin preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007098043A JP5138262B2 (en) | 2007-04-04 | 2007-04-04 | Topical skin preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008255043A true JP2008255043A (en) | 2008-10-23 |
JP5138262B2 JP5138262B2 (en) | 2013-02-06 |
Family
ID=39978983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007098043A Active JP5138262B2 (en) | 2007-04-04 | 2007-04-04 | Topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5138262B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012136475A (en) * | 2010-12-27 | 2012-07-19 | Nippon Menaade Keshohin Kk | Antimutagenic agent |
CN111956547A (en) * | 2020-08-21 | 2020-11-20 | 广东柏俐臣生物科技有限公司 | Anti-inflammatory and soothing composition and application thereof |
CN113559026A (en) * | 2021-05-17 | 2021-10-29 | 台州学院 | Cyclocarya paliurus antioxidant extract and application thereof |
CN114377054A (en) * | 2020-10-16 | 2022-04-22 | 四川大学华西医院 | Application of cyclocarya paliurus leaves or extracts thereof in preparation of medicines or cosmetics for preventing and/or treating acne |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002241298A (en) * | 2001-02-15 | 2002-08-28 | Nissei Marine Kogyo Kk | Composition effective for reducing blood glucose |
JP2002281938A (en) * | 2001-03-27 | 2002-10-02 | Global Core:Kk | Food for improving physical constitution |
JP2004075640A (en) * | 2002-08-22 | 2004-03-11 | Fancl Corp | Agent for inhibiting differentiation of lipocyte |
-
2007
- 2007-04-04 JP JP2007098043A patent/JP5138262B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002241298A (en) * | 2001-02-15 | 2002-08-28 | Nissei Marine Kogyo Kk | Composition effective for reducing blood glucose |
JP2002281938A (en) * | 2001-03-27 | 2002-10-02 | Global Core:Kk | Food for improving physical constitution |
JP2004075640A (en) * | 2002-08-22 | 2004-03-11 | Fancl Corp | Agent for inhibiting differentiation of lipocyte |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012136475A (en) * | 2010-12-27 | 2012-07-19 | Nippon Menaade Keshohin Kk | Antimutagenic agent |
CN111956547A (en) * | 2020-08-21 | 2020-11-20 | 广东柏俐臣生物科技有限公司 | Anti-inflammatory and soothing composition and application thereof |
CN114377054A (en) * | 2020-10-16 | 2022-04-22 | 四川大学华西医院 | Application of cyclocarya paliurus leaves or extracts thereof in preparation of medicines or cosmetics for preventing and/or treating acne |
CN114377054B (en) * | 2020-10-16 | 2023-08-15 | 四川大学华西医院 | Use of cyclocarya paliurus leaves or extracts thereof in preparation of drugs or cosmetics for preventing and/or treating acne |
CN113559026A (en) * | 2021-05-17 | 2021-10-29 | 台州学院 | Cyclocarya paliurus antioxidant extract and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5138262B2 (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003300858A (en) | Skin care preparation | |
JP2003081749A (en) | Skin care preparation | |
JP5184840B2 (en) | Topical skin preparation | |
JP5138262B2 (en) | Topical skin preparation | |
JP5154835B2 (en) | Whitening cosmetics | |
JP5144362B2 (en) | Topical skin preparation | |
JP2005023021A (en) | Elastase inhibitor | |
KR101775485B1 (en) | Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient | |
JP2003095857A (en) | Skin care preparation | |
JP7148115B2 (en) | Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition | |
JP5468866B2 (en) | Topical skin preparation | |
JP5415216B2 (en) | Topical skin preparation | |
JP5690149B2 (en) | External preparation or internal preparation | |
JP4224387B2 (en) | Topical skin preparation | |
JP6468595B2 (en) | Topical skin preparation | |
JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
JP5710193B2 (en) | Topical skin preparation | |
JP4047230B2 (en) | Skin preparation | |
JP7539127B2 (en) | Cell proliferation promoters, MMP-2 inhibitors, skin preparations for external use, medicines and internal preparations | |
JP7433628B2 (en) | Skin external preparations and internal preparations | |
JP4402274B2 (en) | Topical skin preparation | |
JP5600421B2 (en) | Skin preparation | |
JP5690150B2 (en) | External preparation or internal preparation | |
JP2003055184A (en) | Skin care preparation | |
JP4698810B2 (en) | Topical skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121018 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121113 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121114 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5138262 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |